Back to Search Start Over

Implementation of a financial navigation program in gynecologic oncology.

Authors :
Noor Chelsea N
Posever N
Hsieh TYJ
Patterson S
Sweeney C
Dalrymple JL
Dottino J
Wiechert AC
Garrett L
Hacker MR
Esselen KM
Source :
Gynecologic oncology [Gynecol Oncol] 2024 Oct; Vol. 189, pp. 119-124. Date of Electronic Publication: 2024 Aug 02.
Publication Year :
2024

Abstract

Background: "Financial Toxicity" (FT) is the financial burden imposed on patients due to disease and its treatment. Approximately 50% of gynecologic oncology patients experience FT. This study describes the implementation and outcomes of a novel financial navigation program (FNP) in gynecologic oncology.<br />Methods: Patients presenting for initial consultation with a gynecologic oncologist from July 2022 to September 2023 were included. A FNP was launched inclusive of hiring a financial navigator (FN) in July 2022, and implementing FT screening in October 2022. We prospectively captured patient referrals to the FN, collecting clinical, demographic, financial and social needs information, along with FN interventions and institutional support service referrals. Referrals to the FN and support services were quantified before and after screening implementation.<br />Results: There were 1029 patients with 21.6% seen before and 78.4% after screening initiation. Median age was 58 (IQR 46-68). The majority were non-Hispanic white (60%) with private insurance (61%). A total of 10.5% patients were referred to the FN. Transportation (32%), financial assistance (20.5%) and emotional support (15.4%) were the most common needs identified. A higher proportion of patients referred to the FN identified as Black, had government-funded insurance or diagnoses of uterine or cervical cancers (p < 0.05). Post-screening referrals to FN increased (5% vs. 12.9%, p < 0.001), while referrals to other support services decreased (9.5% vs. 2.9%, p < 0.001).<br />Conclusions: Implementation of the FNP was feasible, though presence of both a FN and FT screening maximized its effectiveness. Further investigation is needed to understand screening barriers and evaluate longer-term impact.<br />Competing Interests: Declaration of competing interest There are no conflicts of interest to disclose.<br /> (Copyright © 2024. Published by Elsevier Inc.)

Details

Language :
English
ISSN :
1095-6859
Volume :
189
Database :
MEDLINE
Journal :
Gynecologic oncology
Publication Type :
Academic Journal
Accession number :
39096589
Full Text :
https://doi.org/10.1016/j.ygyno.2024.07.672